Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100209-2M peptide

Journal of Immunotherapy

Volumn 30, Issue 5, 2007, Pages 533-543

  Meijer, Sybren L ^a   Dols, Annemieke ^a   Jensen, Shawn M ^a,b   Hu, Hong Ming ^a   Miller, William ^a   Walker, Edwin ^a   Romero, Pedro ^c   Fox, Bernard A ^a,b,d   Urba, Walter J ^a,e  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e EARLE A CHILES RESEARCH INSTITUTE   (United States)

Author keywords

Immunotherapy; Melanoma; Peptide vaccine

Indexed keywords

CD8 ANTIGEN; GLYCOPROTEIN GP 100; INTERFERON;

ANTIBODY PRODUCTION; ANTIGEN RECOGNITION; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER PATIENT; CANCER STAGING; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IMMUNOSTIMULATION; IN VITRO STUDY; INTERFERON PRODUCTION; MELANOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENTINEL LYMPH NODE BIOPSY;

ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; HUMANS; INTERFERON TYPE II; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MEMBRANE GLYCOPROTEINS; SKIN NEOPLASMS;

EID: 34250897431     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3180335b5e     Document Type: Article

References (39)

1. Boon T, Old LJ. Cancer tumor antigens. Curr Opin Immunol. 1997;9:681-683.
2. Bakker AB, Schreurs MW, de Boer AJ, et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med. 1994;179:1005-1009.
3. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA. 1994;91:6458-6462.
4. Salgaller ML, Marincola FM, Cormier JN, et al. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 1996;56:4749-4757.
5. Clay TM, Custer MC, McKee MD, et al. Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. J Immunol. 1999;162:1749-1755.
6. Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am. 1997;3:37-44.
7. Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res. 1998;58:4902-4908.
8. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4:321-327.
9. Wang F, Bade E, Kuniyoshi C, et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res. 1999;5:2756-2765.
10. Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol. 1996;157:2539-2548.
11. Valmori D, Fonteneau JF, Lizana CM, et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol. 1998;160:1750-1758.
12. Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999;5:677-685.
13. Rubio-Godoy V, Dutoit V, Rimoldi D, et al. Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life. Proc Natl Acad Sci USA. 2001;98:10302-10307.
14. Dutoit V, Rubio-Godoy V, Doucey MA, et al. Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR. J Immunol. 2002;168:1167-1171.
15. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274:94-96.
16. Callan MF, Tan L, Annels N, et al. Direct visualization of antigenspecific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo. J Exp Med. 1998;187:1395-1402.
17. Ogg GS, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 1998;279:2103-2106.
18. Lee KH, Wang E, Nielsen MB, et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol. 1999;163:6292-6300.
19. Smith JW II, Walker EB, Fox BA, et al. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol. 2003;21:1562-1573.
20. Parmiani G, Castelli C, Dalerba P, et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? where are we going? J Natl Cancer Inst. 2002;94:805-818.
21. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
22. Nielsen MB, Monsurro V, Migueles SA, et al. Status of activation of circulating vaccine-elicited CD8+ T cells. J Immunol. 2000;165:2287-2296.
23. Schrama D, Andersen MH, Terheyden P, et al. Oligoclonal T-cell receptor usage of melanocyte differentiation antigen-reactive T cells in stage IV melanoma patients. Cancer Res. 2001;61:493-496.
24. Pittet MJ, Speiser DE, Valmori D, et al. Ex vivo analysis of tumor antigen specific CD8+ T cell responses using MHC/peptide tetramers in cancer patients. Int Immunopharmacol. 2001;1:1235-1247.
25. Pullarkat V, Lee PP, Scotland R, et al. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin Cancer Res. 2003;9:1301-1312.
26. Lienard D, Rimoldi D, Marchand M, et al. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun. 2004;4:4.
27. Speiser DE, Romero P. Toward improved immunocompetence of adoptively transferred CD8+ T cells. J Clin Invest. 2005;115:1467-1469.
28. Hu HM, Dols A, Meijer S, et al. Immunological monitoring of patients with melanoma after peptide vaccination using soluble peptide/HLA-A2 dimer complexes. J Immunother. 2004;27:48-59.
29. Meijer SL, Dols A, Urba WJ, et al. Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells. J Immunother. 2002;25:359-372.
30. Walker EB, Haley D, Miller W, et al. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells. Clin Cancer Res. 2004;10:668-680.
31. Yang S, Linette GP, Longerich S, et al. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity. J Immunol. 2002;169:531-539.
32. Zeh HJ III, Perry-Lalley D, Dudley ME, et al. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol. 1999;162:989-994.
33. Alexander-Miller MA, Leggatt GR, Sarin A, et al. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J Exp Med. 1996;184:485-492.
34. Toes RE, Offringa R, Blom RJ, et al. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA. 1996;93:7855-7860.
35. Toes RE, Blom RJ, Offringa R, et al. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol. 1996;156:3911-3918.
36. Savage PA, Boniface JJ, Davis MM. A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity. 1999;10:485-492.
37. Powell DJ Jr, Rosenberg SA. Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination. J Immunother. 2004;27:36-47.
38. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA. 1996;93:4102-4107.
39. Dutoit V, Rubio-Godoy V, Dietrich PY, et al. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res. 2001;61:5850-5856.